| Trial ID: | L2734 |
| Source ID: | NCT00657280
|
| Associated Drug: |
Sitagliptin
|
| Title: |
Study of the Effect of Sitagliptin on Glucose (Sugar) Metabolism in Patients With Heart Failure
|
| Acronym: |
S-001
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00657280/results
|
| Conditions: |
Heart Failure, Congestive
|
| Interventions: |
DRUG: Sitagliptin
|
| Outcome Measures: |
Primary: Determine the Effects of Sitagliptin on Myocardial Glucose Uptake Measured by Myocardial PET Scan, This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blood may help improve the function of the heart as well. If so, this may suggest that even people who do not have frank diabetes but who do have heart failure may benefit from using this medication. Baseline glucose uptake scans will be compared with the scans on sitagliptin thirty days after baseline, 30 days|Determine the Effects of Sitagliptin on Myocardial Glucose Uptake in Patients With Nonischemic Cardiomyopathy, This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blood may help improve the function of the heart as well. If so, this may suggest that even people who do not have frank diabetes but who do have heart failure may benefit from using this medication., 2008-2012 | Secondary: Determine the Effects of Sitagliptin on Microvascular Function in Patients With Nonischemic Cardiomyopathy, 2010-2012|Determine the Effects of Sitagliptin on Microvascular Function in Patients With Nonischemic Cardiomyopathy, This study will investigate the effects of sitagliptin, a medicine commonly used to treat type 2 diabetes, on the utilization of glucose by the heart in patients with heart failure which is not due to heart attacks. We hope to determine whether improving the heart's ability to use glucose in the blood may help improve the function of the heart as well. If so, this may suggest that even people who do not have frank diabetes but who do have heart failure may benefit from using this medication., 4 years
|
| Sponsor/Collaborators: |
Sponsor: Stanford University | Collaborators: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
EARLY_PHASE1
|
| Enrollment: |
16
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2008-04
|
| Completion Date: |
2012-02
|
| Results First Posted: |
2014-12-05
|
| Last Update Posted: |
2014-12-05
|
| Locations: |
Stanford University School of Medicine, Stanford, California, 94305, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00657280
|
